Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Immune checkpoint blockade in esophageal squamous cell carcinoma: is it ready for prime time?

Pectasides E.

J Thorac Dis. 2018 Mar;10(3):1276-1279. doi: 10.21037/jtd.2018.02.74. No abstract available.

2.

Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients.

Kim ST, Banks KC, Pectasides E, Kim SY, Kim K, Lanman RB, Talasaz A, An J, Choi MG, Lee JH, Sohn TS, Bae JM, Kim S, Park SH, Park JO, Park YS, Lim HY, Kim NKD, Park W, Lee H, Bass AJ, Kim K, Kang WK, Lee J.

Ann Oncol. 2018 Apr 1;29(4):1037-1048. doi: 10.1093/annonc/mdy034.

3.

Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma.

Pectasides E, Stachler MD, Derks S, Liu Y, Maron S, Islam M, Alpert L, Kwak H, Kindler H, Polite B, Sharma MR, Allen K, O'Day E, Lomnicki S, Maranto M, Kanteti R, Fitzpatrick C, Weber C, Setia N, Xiao SY, Hart J, Nagy RJ, Kim KM, Choi MG, Min BH, Nason KS, O'Keefe L, Watanabe M, Baba H, Lanman R, Agoston AT, Oh DJ, Dunford A, Thorner AR, Ducar MD, Wollison BM, Coleman HA, Ji Y, Posner MC, Roggin K, Turaga K, Chang P, Hogarth K, Siddiqui U, Gelrud A, Ha G, Freeman SS, Rhoades J, Reed S, Gydush G, Rotem D, Davison J, Imamura Y, Adalsteinsson V, Lee J, Bass AJ, Catenacci DV.

Cancer Discov. 2018 Jan;8(1):37-48. doi: 10.1158/2159-8290.CD-17-0395. Epub 2017 Oct 4.

4.

CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma.

Zhou J, Wu Z, Wong G, Pectasides E, Nagaraja A, Stachler M, Zhang H, Chen T, Zhang H, Liu JB, Xu X, Sicinska E, Sanchez-Vega F, Rustgi AK, Diehl JA, Wong KK, Bass AJ.

Nat Commun. 2017 Jan 6;8:13897. doi: 10.1038/ncomms13897.

5.

Sequencing Treatment in BRAFV600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition.

Johnson DB, Pectasides E, Feld E, Ye F, Zhao S, Johnpulle R, Merritt R, McDermott DF, Puzanov I, Lawrence D, Sosman JA, Buchbinder E, Sullivan RJ.

J Immunother. 2017 Jan;40(1):31-35.

PMID:
27846054
6.

The emerging role of immunotherapy in gastric and esophageal adenocarcinoma.

Bockorny B, Pectasides E.

Future Oncol. 2016 Aug;12(15):1833-46. doi: 10.2217/fon-2016-0103. Epub 2016 May 11. Review.

PMID:
27166503
7.

Genomic Alterations and Targeted Therapy in Gastric and Esophageal Adenocarcinoma.

Pectasides E.

Clin Ther. 2016 Jul;38(7):1589-99. doi: 10.1016/j.clinthera.2016.03.016. Epub 2016 Mar 31. Review.

PMID:
27041412
8.

Spontaneous Regression of Hepatocellular Carcinoma with Multiple Lung Metastases: A Case Report and Review of the Literature.

Pectasides E, Miksad R, Pyatibrat S, Srivastava A, Bullock A.

Dig Dis Sci. 2016 Sep;61(9):2749-54. doi: 10.1007/s10620-016-4141-2. Epub 2016 Apr 1. Review.

PMID:
27038447
9.

ERBB2 emerges as a new target for colorectal cancer.

Pectasides E, Bass AJ.

Cancer Discov. 2015 Aug;5(8):799-801. doi: 10.1158/2159-8290.CD-15-0730.

10.

Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma.

Kim J, Fox C, Peng S, Pusung M, Pectasides E, Matthee E, Hong YS, Do IG, Jang J, Thorner AR, Van Hummelen P, Rustgi AK, Wong KK, Zhou Z, Tang P, Kim KM, Lee J, Bass AJ.

J Clin Invest. 2014 Dec;124(12):5145-58. doi: 10.1172/JCI75200. Epub 2014 Nov 17.

11.

Src mutation induces acquired lapatinib resistance in ERBB2-amplified human gastroesophageal adenocarcinoma models.

Hong YS, Kim J, Pectasides E, Fox C, Hong SW, Ma Q, Wong GS, Peng S, Stachler MD, Thorner AR, Van Hummelen P, Bass AJ.

PLoS One. 2014 Oct 28;9(10):e109440. doi: 10.1371/journal.pone.0109440. eCollection 2014.

12.

Induction cetuximab, paclitaxel, and carboplatin followed by chemoradiation with cetuximab, paclitaxel, and carboplatin for stage III/IV head and neck squamous cancer: a phase II ECOG-ACRIN trial (E2303).

Wanebo HJ, Lee J, Burtness BA, Ridge JA, Ghebremichael M, Spencer SA, Psyrri D, Pectasides E, Rimm D, Rosen FR, Hancock MR, Tolba KA, Forastiere AA.

Ann Oncol. 2014 Oct;25(10):2036-41. doi: 10.1093/annonc/mdu248. Epub 2014 Jul 9.

13.

Markers of epithelial to mesenchymal transition in association with survival in head and neck squamous cell carcinoma (HNSCC).

Pectasides E, Rampias T, Sasaki C, Perisanidis C, Kouloulias V, Burtness B, Zaramboukas T, Rimm D, Fountzilas G, Psyrri A.

PLoS One. 2014 Apr 10;9(4):e94273. doi: 10.1371/journal.pone.0094273. eCollection 2014.

14.

Prognostic biomarkers in phase II trial of cetuximab-containing induction and chemoradiation in resectable HNSCC: Eastern cooperative oncology group E2303.

Psyrri A, Lee JW, Pectasides E, Vassilakopoulou M, Kosmidis EK, Burtness BA, Rimm DL, Wanebo HJ, Forastiere AA.

Clin Cancer Res. 2014 Jun 1;20(11):3023-32. doi: 10.1158/1078-0432.CCR-14-0113. Epub 2014 Apr 3.

15.

A new mathematical model for the interpretation of translational research evaluating six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon.

Pancoska P, Kirkwood JM, Bouros S, Spyropoulou-Vlachou M, Pectasides E, Tsoutsos D, Polyzos A, Markopoulos C, Panagiotou P, Castana O, Bafaloukos D, Fountzilas G, Gogas H.

PLoS One. 2014 Jan 27;9(1):e86375. doi: 10.1371/journal.pone.0086375. eCollection 2014.

16.

Evaluation of serum Amphiregulin levels in breast cancer patients and cancer-free controls.

Peterson EA, Pectasides E, Shabbeer S, Wiechmann L, Sparano JA, Kenny PA.

Exp Hematol Oncol. 2013 Sep 8;2(1):25. doi: 10.1186/2162-3619-2-25.

17.

Molecular profile of head and neck squamous cell carcinomas bearing p16 high phenotype.

Rampias T, Pectasides E, Prasad M, Sasaki C, Gouveris P, Dimou A, Kountourakis P, Perisanidis C, Burtness B, Zaramboukas T, Rimm D, Fountzilas G, Psyrri A.

Ann Oncol. 2013 Aug;24(8):2124-31. doi: 10.1093/annonc/mdt013. Epub 2013 Feb 13.

PMID:
23406730
18.

Nuclear epidermal growth factor receptor and p16 expression in head and neck squamous cell carcinoma.

Husain H, Psyrri A, Markovic A, Rampias T, Pectasides E, Wang H, Slebos R, Yarbrough WG, Burtness B, Chung CH.

Laryngoscope. 2012 Dec;122(12):2762-8. doi: 10.1002/lary.23647. Epub 2012 Oct 19.

19.

Developments in the systemic treatment of metastatic cervical cancer.

Mountzios G, Soultati A, Pectasides D, Pectasides E, Dimopoulos MA, Papadimitriou CA.

Cancer Treat Rev. 2013 Aug;39(5):430-43. doi: 10.1016/j.ctrv.2012.05.009. Epub 2012 Jun 22. Review.

PMID:
22727690
20.

Quantitative assessment shows loss of antigenic epitopes as a function of pre-analytic variables.

Bai Y, Tolles J, Cheng H, Siddiqui S, Gopinath A, Pectasides E, Camp RL, Rimm DL, Molinaro AM.

Lab Invest. 2011 Aug;91(8):1253-61. doi: 10.1038/labinvest.2011.75. Epub 2011 Apr 25.

21.

Comparative prognostic value of epidermal growth factor quantitative protein expression compared with FISH for head and neck squamous cell carcinoma.

Pectasides E, Rampias T, Kountourakis P, Sasaki C, Kowalski D, Fountzilas G, Zaramboukas T, Rimm D, Burtness B, Psyrri A.

Clin Cancer Res. 2011 May 1;17(9):2947-54. doi: 10.1158/1078-0432.CCR-10-2040. Epub 2011 Feb 25.

22.

Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial.

Gogas H, Dafni U, Koon H, Spyropoulou-Vlachou M, Metaxas Y, Buchbinder E, Pectasides E, Tsoutsos D, Polyzos A, Stratigos A, Markopoulos C, Panagiotou P, Fountzilas G, Castana O, Skarlos P, Atkins MB, Kirkwood JM.

J Transl Med. 2010 Nov 3;8:108. doi: 10.1186/1479-5876-8-108.

23.

Developments in the systemic treatment of endometrial cancer.

Mountzios G, Pectasides D, Bournakis E, Pectasides E, Bozas G, Dimopoulos MA, Papadimitriou CA.

Crit Rev Oncol Hematol. 2011 Sep;79(3):278-92. doi: 10.1016/j.critrevonc.2010.07.013. Epub 2010 Sep 15. Review.

PMID:
20833559
24.

Carboplatin/gemcitabine alternating with carboplatin/pegylated liposomal doxorubicin and carboplatin/cyclophosphamide in platinum-refractory/resistant paclitaxel - pretreated ovarian carcinoma.

Pectasides D, Pectasides E, Papaxoinis G, Psyrri A, Pliarchopoulou K, Koumarianou A, Macheras A, Athanasas G, Xiros N, Economopoulos T.

Gynecol Oncol. 2010 Jul;118(1):52-7. doi: 10.1016/j.ygyno.2010.03.003. Epub 2010 Apr 20.

PMID:
20406710
25.

Nuclear localization of signal transducer and activator of transcription 3 in head and neck squamous cell carcinoma is associated with a better prognosis.

Pectasides E, Egloff AM, Sasaki C, Kountourakis P, Burtness B, Fountzilas G, Dafni U, Zaramboukas T, Rampias T, Rimm D, Grandis J, Psyrri A.

Clin Cancer Res. 2010 Apr 15;16(8):2427-34. doi: 10.1158/1078-0432.CCR-09-2658. Epub 2010 Apr 6.

26.

Activation of Wnt signaling pathway by human papillomavirus E6 and E7 oncogenes in HPV16-positive oropharyngeal squamous carcinoma cells.

Rampias T, Boutati E, Pectasides E, Sasaki C, Kountourakis P, Weinberger P, Psyrri A.

Mol Cancer Res. 2010 Mar;8(3):433-43. doi: 10.1158/1541-7786.MCR-09-0345. Epub 2010 Mar 9.

27.

Primary fallopian tube carcinoma: results of a retrospective analysis of 64 patients.

Pectasides D, Pectasides E, Papaxoinis G, Andreadis C, Papatsibas G, Fountzilas G, Pliarchopoulou K, Macheras A, Aravantinos G, Economopoulos T.

Gynecol Oncol. 2009 Oct;115(1):97-101. doi: 10.1016/j.ygyno.2009.06.025. Epub 2009 Jul 16.

PMID:
19615725
28.

Carboplatin and paclitaxel in metastatic or recurrent cervical cancer.

Pectasides D, Fountzilas G, Papaxoinis G, Pectasides E, Xiros N, Sykiotis C, Koumarianou A, Psyrri A, Panayiotides J, Economopoulos T.

Int J Gynecol Cancer. 2009 May;19(4):777-81. doi: 10.1111/IGC.0b013e3181a40a8b.

PMID:
19509587
29.

Combination chemotherapy with docetaxel, vinorelbine and estramustine phosphate in metastatic androgen-resistant prostate cancer: a single institution experience.

Pectasides D, Pectasides E, Papaxoinis G, Koumarianou A, Psyrri A, Xiros N, Tountas N, Kamposioras K, Papatsibas G, Floros T, Gouveris P, Karageorgopoulou S, Economopoulos T.

Anticancer Res. 2009 Feb;29(2):769-75.

30.

Analysis of 7 immunohistochemical markers in male germ cell tumors demonstrates the prognostic significance of p53 and MIB-1.

Pectasides D, Papaxoinis G, Nikolaou M, Valavanis C, Aravantinos G, Fountzilas G, Tamvakis N, Pectasides E, Lekka I, Arapantoni-Dadioti P, Zizi A, Ghiconti I, Economopoulos T.

Anticancer Res. 2009 Feb;29(2):737-44.

31.

Testicular function in poor-risk nonseminomatous germ cell tumors treated with methotrexate, paclitaxel, ifosfamide, and cisplatin combination chemotherapy.

Pectasides D, Pectasides E, Papaxoinis G, Skondra M, Gerostathou M, Karageorgopoulou S, Kamposioras C, Tountas N, Koumarianou A, Psyrri A, Macheras A, Economopoulos T.

J Androl. 2009 May-Jun;30(3):280-6. doi: 10.2164/jandrol.108.006437. Epub 2009 Jan 8.

32.

Methotrexate, paclitaxel, ifosfamide, and cisplatin in poor-risk nonseminomatous germ cell tumors.

Pectasides D, Pectasides E, Papaxoinis G, Xiros N, Kamposioras K, Tountas N, Economopoulos T.

Urol Oncol. 2010 Nov-Dec;28(6):617-23. doi: 10.1016/j.urolonc.2008.10.013. Epub 2008 Dec 25.

PMID:
19110454
33.

Stage I testicular seminoma: management and controversies.

Pectasides D, Pectasides E, Constantinidou A, Aravantinos G.

Crit Rev Oncol Hematol. 2009 Jul;71(1):22-8. doi: 10.1016/j.critrevonc.2008.10.007. Epub 2008 Nov 28. Review.

PMID:
19046898
34.

Current management of stage I testicular non-seminomatous germ cell tumours.

Pectasides D, Pectasides E, Constantinidou A, Aravantinos G.

Crit Rev Oncol Hematol. 2009 May;70(2):114-23. doi: 10.1016/j.critrevonc.2008.07.018. Epub 2008 Sep 19. Review.

PMID:
18805019
35.

Complete response after imatinib mesylate administration in a patient with chemoresistant stage IV seminoma.

Pectasides D, Nikolaou M, Pectasides E, Koumarianou A, Valavanis C, Economopoulos T.

Anticancer Res. 2008 Jul-Aug;28(4C):2317-20.

36.

Primary ovarian lymphoma: report of two cases and review of the literature.

Pectasides D, Iacovidou I, Psyrri A, Gaglia A, Pectasides E, Papaxoinis G, Drakou A, Xiros N, Economopoulos T.

J Chemother. 2008 Aug;20(4):513-7. Review.

PMID:
18676235
37.

Chemotherapy for recurrent cervical cancer.

Pectasides D, Kamposioras K, Papaxoinis G, Pectasides E.

Cancer Treat Rev. 2008 Nov;34(7):603-13. doi: 10.1016/j.ctrv.2008.05.006. Epub 2008 Jul 26. Review.

PMID:
18657909
38.

Combination chemotherapy with carboplatin, paclitaxel and pegylated liposomal doxorubicin for advanced or recurrent carcinosarcoma of the uterus: clinical experience of a single institution.

Pectasides D, Pectasides E, Papaxoinis G, Xiros N, Sykiotis C, Papachristodoulou A, Tountas N, Panayiotides J, Economopoulos T.

Gynecol Oncol. 2008 Sep;110(3):299-303. doi: 10.1016/j.ygyno.2008.05.017. Epub 2008 Jul 7.

PMID:
18602677
39.

Primary non-Hodgkin's lymphoma of the bladder: report of two cases and review of the literature.

Pectasides D, Iacovidou I, Psyrri A, Pectasides E, Papaxoinis G, Economopoulos T.

J BUON. 2008 Apr-Jun;13(2):277-9.

40.

Adult granulosa cell tumors of the ovary: a clinicopathological study of 34 patients by the Hellenic Cooperative Oncology Group (HeCOG).

Pectasides D, Papaxoinis G, Fountzilas G, Aravantinos G, Pectasides E, Mouratidou D, Economopoulos T, Andreadis Ch.

Anticancer Res. 2008 Mar-Apr;28(2B):1421-7.

41.

Germ cell tumors of the ovary.

Pectasides D, Pectasides E, Kassanos D.

Cancer Treat Rev. 2008 Aug;34(5):427-41. doi: 10.1016/j.ctrv.2008.02.002. Epub 2008 Apr 18. Review.

PMID:
18378402
42.

Carboplatin and paclitaxel in advanced or metastatic endometrial cancer.

Pectasides D, Xiros N, Papaxoinis G, Pectasides E, Sykiotis C, Koumarianou A, Psyrri A, Gaglia A, Kassanos D, Gouveris P, Panayiotidis J, Fountzilas G, Economopoulos T.

Gynecol Oncol. 2008 May;109(2):250-4. doi: 10.1016/j.ygyno.2008.01.028. Epub 2008 Mar 4.

PMID:
18299146
43.

Merkel cell carcinoma of the skin: a retrospective study of 24 cases by the Hellenic Cooperative Oncology Group.

Pectasides D, Papaxoinis G, Pectasides E, Galani H, Razi E, Katodrytis N, Fountzilas G, Economopoulos T.

Oncology. 2007;72(3-4):211-8. doi: 10.1159/000112944. Epub 2008 Jan 7.

PMID:
18176086
44.

Granulosa cell tumor of the ovary.

Pectasides D, Pectasides E, Psyrri A.

Cancer Treat Rev. 2008 Feb;34(1):1-12. Epub 2007 Oct 22. Review.

PMID:
17945423
45.

Gemcitabine and pegylated liposomal doxorubicin alternating with cisplatin plus cyclophosphamide in platinum refractory/resistant, paclitaxel-pretreated, ovarian carcinoma.

Pectasides D, Xiros N, Papaxoinis G, Aravantinos G, Sykiotis C, Pectasides E, Psyrri A, Koumarianou A, Gaglia A, Gouveris P, Economopoulos T.

Gynecol Oncol. 2008 Jan;108(1):47-52. Epub 2007 Oct 25.

PMID:
17915300
46.

Successful treatment with cyclosporine of thymoma-related aplastic anemia.

Gaglia A, Bobota A, Pectasides E, Kosmas C, Papaxoinis G, Pectasides D.

Anticancer Res. 2007 Jul-Aug;27(4C):3025-8.

47.

Systemic therapy in metastatic or recurrent endometrial cancer.

Pectasides D, Pectasides E, Economopoulos T.

Cancer Treat Rev. 2007 Apr;33(2):177-90. Epub 2006 Dec 29. Review.

PMID:
17196749
48.

Maintenance or consolidation therapy in advanced ovarian cancer.

Pectasides D, Pectasides E.

Oncology. 2006;70(5):315-24. Epub 2006 Dec 12. Review.

PMID:
17164587
49.

Cisplatin-based chemotherapy for merkel cell carcinoma of the skin.

Pectasides D, Pectasides M, Psyrri A, Koumarianou A, Xiros N, Pectasides E, Gaglia A, Lianos E, Papaxoinis G, Lampadiari V, Economopoulos T.

Cancer Invest. 2006 Dec;24(8):780-5.

PMID:
17162559
50.

Treatment issues in clear cell carcinoma of the ovary: a different entity?

Pectasides D, Pectasides E, Psyrri A, Economopoulos T.

Oncologist. 2006 Nov-Dec;11(10):1089-94. Review.

Supplemental Content

Loading ...
Support Center